Client News

Posted: September 29, 2016, 4:46 pm
Posted: September 29, 2016, 4:05 pm
Posted: September 29, 2016, 1:33 pm
[at noodls] - TEL AVIV, Israel, Sept. 29, 2016/PRNewswire / -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of a once-daily, ...
Posted: September 29, 2016, 1:10 pm
[PR Newswire] - TEL AVIV, Israel, Sept. 29, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that, to date, it has raised approximately $5.0 million under the Company's At-The-Market financing executed by Cantor Fitzgerald (the "ATM"). In total, to date the Company has issued 933,160 ordinary shares under the ATM at an average sale price of $5.11 per share. This news release does not and shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of the securities in any state or other jurisdiction in which such offer, solicitation or sale is unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
Posted: September 29, 2016, 1:00 pm
[at noodls] - TEL AVIV, Israel, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (NasdaqGM:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, ...
Posted: September 29, 2016, 12:19 am
[GlobeNewswire] - TEL AVIV, Israel, Sept. 28, 2016-- Alcobra Ltd., an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit ...
Posted: September 29, 2016, 12:01 am
[at noodls] - The companies have entered into an agreement to offer biotech and pharmaceutical companies access to BARC's network of global central laboratories covering 7 locations in 2 hemispheres in combination with ...
Posted: September 27, 2016, 2:39 pm
[at noodls] - RUTHERFORD, N.J., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ('Cancer Genetics' or the 'Company'), a leader in enabling precision medicine for oncology through molecular markers ...
Posted: September 27, 2016, 2:39 pm
[at noodls] - The companies have entered into an agreement and partnership to offer biotech and pharmaceutical companies access to ApoCell's ApoStream™ technology for the detection, isolation and enrichment of rare ...
Posted: September 27, 2016, 2:39 pm
[at noodls] - RUTHERFORD, N.J., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ('CGI' or 'The Company'), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, ...
Posted: September 27, 2016, 2:39 pm
[at noodls] - - Eric K. Rowinsky, M.D. appointed Chairman of the Board - DUBLIN, Ohio--(BUSINESS WIRE)--Sep. 26, 2016-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today announced that its Board of Directors has ...
Posted: September 26, 2016, 9:29 pm
[Business Wire] - Navidea Biopharmaceuticals, Inc. today announced that its Board of Directors has appointed Michael M. Goldberg, M.D. as President and Chief Executive Officer effective September 22, 2016.
Posted: September 26, 2016, 9:00 pm